Kamfanin hada magunguna na kasar Sipaniya Rovi da na Roche na kasar Switzerland sun amince da cewa sabon maganin zai yi tasiri kiba da ciwon suga, a halin yanzu a cikin ci gaba na ci gaba na asibiti, za a kera shi a Spain. Yarjejeniyar, ta sanar da CNMV kuma tana jiran tsari a cikin kwanaki masu zuwa, wurare San Sebastián de los Reyes (Madrid) a matsayin cibiyar samarwa don rarraba duniya gaba.
Dangane da hasashen da kamfanoni da Gwamnati suka gabatar, shirin zai haifar da a Tasirin tattalin arziki ya wuce Euro biliyan 2.000 a Spain kuma za ta haɓaka ƙirƙirar ƙwararrun ƙwararrun aikin yi. Ga Rovi, yarjejeniyar tana wakiltar babban haɓaka ga kasuwancin masana'anta na ɓangare na uku, tare da a Ana hasashen haɓakar tallace-tallace a 20% -25% a cikin 2030.
Yarjejeniyar, daki-daki
Rovi, ta hannun reshensa Rois, zai ba da damar Roche layin cike da sauri Yana aiki a San Sebastián de los Reyes. Production zai kasance gaba ɗaya a Spain da kuma maganin kiba Za a tallata shi a duk duniya da zarar an kammala ci gaban aikin sa na asibiti kuma an sami izini masu dacewa.
- Cikakken samarwa a shuka San Sebastián de los Reyes (Madrid).
- Amfani da a layin cike da sauri ga allurai.
- Jiyya a ci gaba na asibiti ci gaban lokaci.
- Rarraba duniya ta hanyar sadarwar duniya ta Roche.
Daga Rovi suka jadada matsayinsu a matsayin dabarun masana'antu abokin tarayya, sakamakon shekaru na zuba jari a cikin iyawa da fasaha da aka mayar da hankali kan allurar. Roche, a nata bangare, yana ƙarfafa kasancewarsa a Spain cikakken sarkar darajar rufe bincike, ganewar asali, samarwa da tallace-tallace.
Tasirin tattalin arziki da kasuwanci akan Rovi
Hukumar zartaswa ta kiyasta cewa aikin zai bunkasa tattalin arzikin da fiye da haka 2.000 miliyan kudin Tarayyar Turai tsakanin tasirin kai tsaye da kai tsaye, fifita sha'awar saka hannun jari da canja wurin ilimi. Ga Rovi, odar zai haifar da ƙaramar haɓaka tsakanin 20% da 25% na tallace-tallace daga kasuwancin masana'anta zuwa wasu kamfanoni nan da 2030.
A cikin sharuddan kuɗi, wannan kewayon yayi daidai da gudummawar tsakanin 67,2 da 84,5 Yuro miliyan a shekarar 2030, bisa ga kiyasin kamfanin. Kasuwar hannayen jari ta amsa da kyau ga sanarwar, tare da haɓaka hannun jari na Rovi. kusan 6%.
Bugu da ƙari ga tasirin macroeconomic, ƙawancen yana ba da damar samar da kwararrun aikin yi da kuma ƙarfafa manyan kayan aikin masana'antu masu daraja, ƙarfafa matsayin Spain a fagen Ƙirƙirar ilimin halittu da fitar da manyan hanyoyin kwantar da hankali.
Tallafin hukumomi da ajanda na masana'antu
Shugaban gwamnati, Pedro Sanchez, ya sadu a Moncloa tare da Shugaba na Roche, Thomas Schinecker ne adam wata, shugaban Rovi, Juan López-Belmont, da kuma babban manajan Roche Spain, Patrick Wallach. Cikakkun bayanai na yarjejeniyar da kuma dacewa da manufofin jama'a don inganta samar da magunguna na gaba-gaba.
Hukumar Gudanarwa ta tsara wannan aiki a cikin Dabarun Masana'antar Magunguna 2024-2028 kuma a cikin layin Tsarin Farfadowa, Canji da Juriya, yana nuna haÉ—in gwiwar jama'a da masu zaman kansu da jawo jarin waje a matsayin levers don bunkasa tattalin arziki da ingantaccen aiki.
Matsayin aikin da matakai na gaba
Kwangilar tana cikin mataki na ƙarshe kuma ana sa ran aiwatarwa sa hannu na ƙarshe a cikin 'yan kwanaki masu zuwaMagungunan, wanda ke cikin na rayuwa da kuma na zuciya da jijiyoyin jini yankin Fayil na Roche yana ci gaba da haɓakar asibiti tare da tsammanin rarrabawa a duniya da zarar an kammala hanyoyin da aka tsara.
Tare da wannan haɗin gwiwar, Roche zai tabbatar da samar da sabon magani na gaba cututtuka masu yaduwa, yayin da Rovi ke yin amfani da ƙarfin fasaha na masana'antar ta Madrid don haɓaka samarwa tare da ƙa'idodin ingancin ƙasa.
Haɗin kai tsakanin Roche da Rovi ya sanya Spain a cikin matsayi mai ƙarfi a cikin masana'antar biopharmaceutical na Turai: samar da gida na sabon magani, Hasashen duniya, gagarumin tasirin tattalin arziki, da kuma taswirar hanya bayyananne don haɓaka ƙwararrun masana'antu da ƙwararrun ayyukan yi a ƙasar.
